Fulvestrant

Title: Fulvestrant
CAS Registry Number: 129453-61-8
CAS Name: (7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol
Manufacturers' Codes: ICI-182780
Trademarks: Faslodex (AstraZeneca)
Molecular Formula: C32H47F5O3S
Molecular Weight: 606.77
Percent Composition: C 63.34%, H 7.81%, F 15.66%, O 7.91%, S 5.28%
Literature References: Novel steroidal estrogen antagonist reported to lack any partial agonist activity. Prepn: J. Bowler, B. S. Tait, EP 138504; eidem, US 4659516 (1985, 1987 both to ICI). Pharmacology: A. E. Wakeling et al., Cancer Res. 51, 3867 (1991). Clinical pharmacokinetics: A. Howell et al., Br. J. Cancer 74, 300 (1996). Clinical evaluation in breast cancer vs tamoxifen: J. F. Robertson et al., Cancer Res. 61, 6739 (2001). Clinical trial in advanced breast cancer: J. N. Ingle et al., J. Clin. Oncol. 24, 1052 (2006). Review of mechanism of action and clinical evaluation: idem, Br. J. Cancer 85, Suppl. 2, 11-14 (2001); A. Howell, Crit. Rev. Oncol. Hematol. 57, 265-273 (2006); of tolerability profile: I. Vergote, P. Abram, Ann. Oncol. 17, 200-204 (2006).
Therap-Cat: Antineoplastic (hormonal).
Keywords: Antineoplastic (Hormonal); Antiestrogens.
Fulvoplumierin Fumagillin Fumaric Acid Fumigatin Fungichromin

Fulvestrant
Fulvestrant.svg
Systematic (IUPAC) name
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
Clinical data
Trade names Faslodex
AHFS/Drugs.com monograph
Pregnancy cat. D
Legal status Rx only
Routes Intramuscular injection
Pharmacokinetic data
Protein binding 99%
Half-life 40 days
Identifiers
CAS number 129453-61-8 YesY
ATC code L02BA03
PubChem CID 104741
IUPHAR ligand 1015
DrugBank DB00947
ChemSpider 94553 N
UNII 22X328QOC4 YesY
KEGG D01161 N
ChEMBL CHEMBL1358 N
Synonyms ICI-182,780
Chemical data
Formula C32H47F5O3S 
Mol. mass 606.772 g/mol
 N (what is this?)  (verify)

Fulvestrant (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.[1] It is administered as a once-monthly injection.